GeneDx Holdings Corp. [WGS] · Equity Underwriting Memo

Trade Construction

WATCHLIST — research direction NEGATIVE / short-biased, NOT actionable

GeneDx Holdings Corp. [WGS] — Trade Construction & Risk Management (Task 5)

Spot $60.54 (2026-07-27) · Framework references/trade-construction.md as written at v1.4.2, applied unmodified. No proposed amendment has been adopted, anticipated or applied in this run. The v1.4.2 amendment quarantine is observed: nothing here relies on a rule drafted for this name.

0. Portfolio context (read the book first)

portfolio_book.json as of 2026-07-27: zero open positions. Watchlist: MU, ISRG, NET, SMR, NBIS, SNDK, GH, MSFT, GOOGL, NTRA, CIEN, TXG, TWST. Config: max single name 5%, max sector concentration 25%, max pairwise correlation without disclosure 0.60, cash hurdle 4.7%, drawdown ladder −5% review / −10% de-gross / −15% stop.

Marginal correlation of WGS vs. every book name (252 trailing daily log returns to 2026-07-27, Alpaca):

NTRA GH TXG TWST SPY ISRG GOOGL SMR MSFT NBIS CIEN SNDK MU NET
ρ vs WGS +0.34 +0.27 +0.23 +0.23 +0.19 +0.15 +0.14 +0.13 +0.12 +0.10 +0.06 +0.05 +0.03 +0.02

Every pair is far below the 0.60 disclosure threshold. WGS is the most idiosyncratic name in the coverage set — even against NTRA and GH, its nearest sector comparables, correlation is only +0.34, and against the AI-infrastructure cluster it is effectively zero. Diversification is therefore a genuine argument for prioritising this name when it converts — and no argument at all for owning it now, since diversification cannot rescue a position that fails its own gates. Same reasoning already applied to ISRG.

Cluster: life-science tools & diagnostics. GH opened this cluster; NTRA, TXG and TWST are also in it. WGS would be the fifth. With zero positions live there is no breach today, but a future book must count five correlated names before sizing this one.

Capital-competition test vs. the 4.7% cash hurdle: the long-side E[R] of +10.2% clears cash by 5.5pp; the short-side E[R] of −21.7% loses to cash by 26.4pp. Neither passes the gates that would let capital be committed (§2). The book write-back is a Watchlist entry, recorded in §7.

1. The four conclusions, kept explicitly separate

1 — Fundamental conclusion. Demand is not the problem: exome/genome volume is +34% YoY and accelerating. Realised price is the problem. Computed ASP fell from $3,848 (25Q3) to $3,296 (26Q1), −14.3% in two quarters, and the 10-Q attributes it directly: "partially offset by a 5% decrease in average reimbursement rates." Receivables have aged for three consecutive quarters (DSO 36 → 48 → 57 → 68 days, AR +67% YoY on +17% revenue). Operating leverage has inverted (SG&A +48%, R&D +57% against revenue +17%); adjusted net income swung from +$9.2m to −$8.2m; TTM operating cash flow is −$9.3m after a reported +$33.3m in FY2025. A $31.3m write-off of Fabric Genomics 11 months after close cites "changes in commercial strategy and go-to-market execution." Deteriorating economics on a business with intact demand.

2 — Expectations conclusion. Consensus (10 analysts) is guidance-anchored: FY2026 $478.4m against a $475–490m guide. FY2027 $594.9m / EPS $1.10. House base: FY2026 $466.8m (−2.4%, and below the guidance floor), FY2027 $562.5m (−5.4%), FY2027 adjusted EPS $0.51 vs $1.10 (−54%). The specific disagreement is precise and checkable: the reset guide still embeds an H2-2026 ASP of $3,506 against an H1 of $3,315, a +5.7% step-up for which no mechanism has been stated anywhere in the release, the 10-Q, or any subsequent 8-K.

3 — Valuation conclusion. Probability-weighted target $66.71 (+10.2%); base $65.06 (+7.5%); bear $39.15; bull $102.79. The market at $60.54 is discounting the house base case at a 7.3% implied WACC — or, equivalently, discounting the bull case at a normal 15.0%. Priced for the bull case, correctly discounted. Full-to-fair, in neither direction decisive.

4 — Portfolio conclusion. No position. The research view is negative; the trade is not. That is the distinction this task exists to preserve.

2. Hard gates

For a SHORT

Gate Result Basis
1 — Causal mechanism PASS (with the scorecard disagreement disclosed) See §2.1
2 — Variant vs. consensus PASS — marginal, 2A See §2.2
3 — Catalyst PASS — unusually clean See §2.3
4 — Scenario-weighted E[R] FAIL — decisively, range entirely negative See §2.4
5 — Implementation feasibility FAIL See §2.5
6 — Momentum / tape PASS — with the conflict named See §2.6

For a LONG

Gate Result Basis
1 — Causal mechanism FAIL The required mechanism is improving fundamentals. The current evidence is a disclosed −5% realised-price decline, a 32-day DSO deterioration, inverted operating leverage, a $31.3m write-off, a 12% guidance cut, and negative TTM operating cash flow. A long-side mechanism would have to be "ASP recovers," which is a hypothesis with no data point showing it underway. The long-side corroboration the gate asks for — strong profitability + low accruals + high F-score — is present only on FY2025 data and is impairment/purchase-accounting distorted (Valuation §7); the TTM F-score is 2/9.
2 — Variant vs. consensus FAIL The house view is below consensus in every scenario except bull. You cannot be long on a negative variant. No 2B duration variant is available either: the four-leg bar fails at leg 1 — the independent corpus (ClinicalTrials.gov) returned zero GeneDx-sponsored studies, and the flagship long-duration option (genomic newborn screening) is run on third-party grants that GeneDx does not control.
3 — Catalyst PASS Same 3-Aug print.
4 — Expected return PASS, but hurdle INSIDE the range +10.2% point; range −4.6% to +20.7%; cash hurdle +4.7% sits inside. Per v1.4.2 item C4 the honest statement is that the long-side E[R] is not determined by the analysis — it is determined by a judgement input. Moot in any case: Gates 1 and 2 fail.
5 — Feasibility PASS on borrow (n/a); options unusable — front-week IV 148–164% at 2.1× realised, 41% bid/ask
6 — Momentum / tape FAIL — fights the tape, unmitigated Buying a name at 0.36× its 52-week high and 0.66× its 200-day, with 12-1 momentum −14% and bottom-of-nine relative momentum against a peer set up a median +101%, is the falling-knife case the gate names. The +75% bounce off the 5-May low and the price sitting 4.2% above the 50-day are a partial counter-signal, but the governing 200-day trend has not cracked upward and no mitigation is proposed.

2.1 Gate 1 — causal mechanism (SHORT): PASS

The named mechanism is realised-price (average reimbursement rate) deterioration decoupling revenue from volume, compounded by inverted operating leverage. It is not hypothetical; it is underway and quantified:

Evidence Value Source
Company-disclosed ASP decline −5% YoY 10-Q Q1-2026, MD&A, verbatim
Computed ASP, peak to trough $3,848 → $3,296 (−14.3%) in two quarters Revenue ÷ volume, both company-disclosed, 8-K Ex-99.1
Revenue vs. volume growth gap, Q1-2026 +27% revenue vs +34% volume for exome/genome 8-K Ex-99.1
DSO 36 → 48 → 43 → 48 → 57 → 68 days; AR +67% YoY Balance sheet, five quarters
Guidance cut $540–555m → $475–490m (−12%), of which ~100% is price — volume guidance moved 34%→"at least 30%" Decomposed in WGS_Model.xlsx, sheet KPI_ASP
Operating leverage SG&A +48%, R&D +57% vs revenue +17% 10-Q Q1-2026
Acquisition write-off $31.3m, 11 months post-close, cause stated as "go-to-market execution" 10-Q Note 6
Management language pricing, ASP, denial, collections: zero mentions in 17 quarters while volume hits a five-year high in the quarter ASP fell 12% Mention-frequency pass

The quantitative-corroboration standard, applied honestly and in the direction the evidence points. The gate specifies accruals and F-score as the corroborating inputs. On a naïve read they contradict the short: FY2025 accruals are −11.5% (clean), gross profitability 56.9% and rising, FY2025 F-score 6/9. I state that disagreement rather than ignoring it — and I state why, because in this specific name both inputs are restructuring/impairment artifacts and are not measuring the ongoing business:

The one earnings-quality metric that is untouched by the discontinuity, the impairment and purchase accounting — receivables ageing — has deteriorated for three consecutive quarters, and it deteriorated before the price break appeared in reported revenue. On the evidence measuring the business as it operates today, the scorecard corroborates the mechanism. Gate 1 passes, and the memo has said explicitly where the standard inputs disagree and why.

2.2 Gate 2 — variant vs. consensus (SHORT): PASS, marginal, on 2A

This rests on 2A (estimate variant), not 2B. No duration variant is claimed: the four-leg bar fails at leg 1 (ClinicalTrials.gov returns zero GeneDx-sponsored studies).

Metric Street House base Gap
FY2026 revenue $478.4m $466.8m −2.4% — and below the $475m guidance floor
FY2027 revenue $594.9m $562.5m −5.4%
FY2027 adjusted EPS $1.1038 $0.51 −54%
FY2026 adjusted net income positive (company-guided) negative company misses its own reset guide

Why consensus is wrong, specifically: consensus is not an independent forecast — at FY2026 $478.4m against a $475–490m guide it is the guidance, transcribed. And that guidance embeds an arithmetic assumption nobody has underwritten: H2-2026 ASP of $3,506 versus H1's $3,315, a +5.7% step-up with no stated mechanism. Consensus also carries an FY2027 operating-leverage inflection — EPS $1.10 on 24% revenue growth, implying ~5.7% net margin from an adjusted-loss run-rate — in the quarter immediately after opex grew 48% against 17% revenue growth. That is the specific thing I think is wrong.

Why this is graded MARGINAL rather than a clean pass, stated against my own interest. Three reasons:

  1. The revenue gap is small. −2.4% on the checkable near-term year. The framework's own precedent (ISRG, rejected on a 0.2% gap) says small revenue gaps are not variants; −2.4% is more than an order of magnitude larger, but it is not a chasm.
  2. The Street has already moved most of the way toward me. FY2026 EPS has been cut −107% and FY2027 −46% in 90 days, with 5 of 9 cutting FY2027 in the last 30 days. I am differentiated on magnitude, not direction.
  3. 74% of the price-target disagreement is multiple, not numbers (decomposed in Valuation §5.3: at the Street's own 4.07x FY2027 EV/Sales, my numbers alone explain only $4.34 of the $16.72 target gap). The framework treats a multiple opinion as weak evidence, and it is right to.

The EPS gap (−54% on FY2027) is what carries this gate. Without it, Gate 2 would fail.

2.3 Gate 3 — catalyst that resolves this specific disagreement: PASS

Q2-2026 results, Monday 3 August 2026, after market close (company-confirmed; conference call 4:30pm ET). Seven days away.

This is not merely a scheduled event near the position — it resolves the exact disagreement:

2.4 Gate 4 — scenario-weighted expected return: FAIL for a short (this is the binding gate)

Reported as a range with a flip point, per v1.4.2 item C4 — not a point estimate.

Scenario p Target Long return Short return
Bear 30% $39.15 −35.3% +35.3%
Base 45% $65.06 +7.5% −7.5%
Bull 25% $102.79 +69.8% −69.8%
Probability-weighted $66.71 +10.2% −10.2%

SHORT, gross: −10.2%. Net of an estimated ~10%/yr borrow (assumption — an actual borrow rate is not obtainable from any free source available here; the 30.79%-of-float / 18.94m-float profile implies it is expensive) and ~1.5% slippage: −21.7%.

Range across the plausible span of scenario weights (bear 20–50%, bull 15–35%, base 30–55%): −32.2% to −6.9%, net of costs.

The hurdle sits entirely OUTSIDE the range. Every plausible weighting produces a negative net expected return for a short. This is not a knife-edge FAIL of the SMR (−0.2%) or ISRG (−0.4%) kind, and the framework now requires that distinction be made: this fails by 22 to 32 percentage points.

Flip point. For the short's net E[R] to reach zero, the bear case must carry a 60% weight with the bull capped at 10% — i.e., I would have to be roughly twice as confident in the bear case as I am, and nearly rule out the bull. I do not have the evidence for either. Even at zero borrow cost the gross E[R] is −10.2% and the gate still fails. The failure is not a cost artifact; it is that the base case target sits above spot.

(For completeness: the long-side E[R] is +10.2% with a range of −4.6% to +20.7%, and there the cash hurdle of +4.7% does sit INSIDE the range — flipping below it at a 43% bear weight. That is the "not determined by the analysis" case. It is moot because the long fails Gates 1, 2 and 6.)

2.5 Gate 5 — implementation feasibility: FAIL

Constraint Value Verdict
Short interest 5.83m shares = 30.79% of float, 19.64% of shares outstanding Crowded
Float 18.94m shares of 29.69m outstanding Small
Days to cover 5.22 High
Short-interest trend 5.94m → 5.83m, already declining The trade is being taken off, not put on
Borrow fee Not obtainable from any free source available. Stated rather than invented. Estimated ~10%/yr from the SI/float profile; sensitivity tested above
Realised volatility 95.9% annualised (252d); 30d 72.2% Extreme
Front-week IV (2026-08-07) 148–164% = 2.1× 30-day realised Long premium is negative-expectancy
Option bid/ask Aug-7 $60 put $4.38 / $6.81 — a 41% spread Effectively untradeable
Implied move into the print 19.9% ($12.04 straddle) Against print-day history of −49.2% / −7.3% / −4.2%: not obviously cheap
Maximum plausible loss Unbounded on equity. On the bull path ($102.79) a short loses 69.8%; a squeeze in a 30.8%-short, 18.9m-float name can overshoot far beyond that. The stock already did +75% in eleven weeks off the 5-May low.
Insider buying under the price ~$106.6m across six clustered, discretionary open-market purchases (Casdin Capital; Keith Meister/Corvex), all after the guidance cut, averaging up from $35 to $56 The single strongest contrary fact in the file

On the options specifically, the gate's own two-part test: the catalyst does occur before expiration (3 Aug, before 7 Aug) — but the second half fails. The expected move must exceed what implied volatility already prices, and a 19.9% implied move at 2.1× realised vol, bought across a 41% spread, does not clear that bar. A name can be a good fundamental short and a bad put purchase. This is that name.

Invalidation condition (stated as the gate requires): a close above $92.20 (the 200-day moving average) would mean the tape has fully rejected the reset thesis and any short bias is wrong.

2.6 Gate 6 — momentum / tape: PASS for a short, with the conflict named explicitly

Metric Value For a short
12-1 momentum (the gate's specified metric) −14.0% With the tape
12-month total return −24.2% With
Relative momentum Last of nine — diagnostics peers median +101%, SPY +17.3% Strongly with
Price ÷ 52-week high 0.361 With
Price ÷ 200-day MA 0.657 With
Price ÷ 50-day MA 1.042 AGAINST
3-month price action +75% off the 5-May low of $34.51 Strongly AGAINST

The conflict, named as the gate requires rather than silently absorbed: on the twelve-month metric the gate specifies, a short is with the tape and the gate passes on its own terms. But the three-month tape is violently against it — this stock has risen 75% in eleven weeks, is above its 50-day, and sits in a peer group that has doubled. Shorting a +75% eleven-week rally in a 30.8%-short-interest, 18.9m-float name is the textbook squeeze setup, and Daniel & Moskowitz (2016) is the reminder that momentum crashes hardest exactly in sharp reversals like this one. Gate 6 passes on the letter and is a loud warning in substance. It does not independently block the trade — Gates 4 and 5 already do — but had those passed, this would have forced a one-tier size reduction and a trend-crack entry rule.

3. INVESTMENT DECISION

INVESTMENT DECISION: Watchlist  (research direction: NEGATIVE / short-biased — NOT actionable)

GATES (for a SHORT):
  1(Mechanism):              PASS   — realised-price deterioration, company-disclosed (-5% avg reimbursement
                                      rate), ASP $3,848 -> $3,296, DSO 36 -> 68 days, opex +48% vs revenue +17%.
                                      Accruals/F-score disagree on a naive read; both are impairment /
                                      purchase-accounting artifacts. TTM F-score 2/9 vs FY2025 6/9.
  2(Variant vs. Consensus):  PASS   — MARGINAL, on 2A. FY2026 rev -2.4% (below the guidance floor),
                                      FY2027 rev -5.4%, FY2027 adj. EPS -54%. The guide embeds an unexplained
                                      +5.7% H2 ASP step-up. Graded marginal: 74% of the target gap is multiple,
                                      not numbers, and the Street has already cut FY26 EPS -107%.
  3(Catalyst):               PASS   — Q2-2026 results, Mon 3 Aug 2026 after the close (7 days). Discloses the
                                      exact metric in dispute: exome/genome revenue / volume = ASP.
  4(Expected Return):        FAIL   — BINDING GATE. Short E[R] -10.2% gross, -21.7% net. Range -32.2% to -6.9%
                                      across all plausible weights. The hurdle sits ENTIRELY OUTSIDE the range:
                                      this fails by 22-32pp, not by tenths. Flip needs bear 60% / bull 10%.
  5(Feasibility):            FAIL   — 30.79% of an 18.94m float short, 5.22 days to cover, SI already falling;
                                      borrow rate not obtainable (est. ~10%, flagged); realised vol 95.9%;
                                      front-week IV 148-164% = 2.1x realised with a 41% bid/ask; ~$106.6m of
                                      clustered insider BUYING sits under the price.
  6(Momentum/Tape):          PASS   — WITH the 12-month tape (12-1 = -14.0%, last of nine peers), but
                                      VIOLENTLY AGAINST the 3-month tape (+75% off the 5-May low, above the
                                      50-day). Conflict named, not absorbed.

GATES (for a LONG):  1 FAIL · 2 FAIL · 3 PASS · 4 PASS (hurdle INSIDE range) · 5 PASS · 6 FAIL (unmitigated)

ENTRY:        None today. Long conversion ~$40 (see §5). Short conversion requires the Gate 4/5 fix in §5.
TARGET:       $66.71 probability-weighted  |  Base $65.06  |  Bear $39.15  |  Bull $102.79
INVALIDATION: $92.20 (200-day MA) kills the negative research view outright.
TIME HORIZON: First checkpoint Monday 3 August 2026 (Q2-2026 results). Full thesis resolution by the FY2026
              print, ~February 2027, when the H2 ASP question is arithmetically settled.

SCENARIO-WEIGHTED E[R]:
  SHORT: -10.2% gross; -21.7% net of ~10% est. borrow + 1.5% slippage.
         Range across plausible weights: -32.2% to -6.9%. Hurdle OUTSIDE the range. Clean FAIL.
  LONG:  +10.2% gross. Range -4.6% to +20.7%. Cash hurdle +4.7% sits INSIDE the range -> per v1.4.2 C4,
         the long-side decision is NOT determined by the analysis. Moot: Gates 1, 2, 6 fail.
  Simple: a short risks ~70% (bull) to make ~35% (bear). A long risks ~35% to make ~70%.

SIZING:  Conviction: LOW (composite 0.51 — see §4)  |  Volatility: HIGH (realised 95.9%, beta 1.98)
         Grid output at LOW x HIGH: "Below minimum size — round down to Watchlist."
         RESULTING SIZE: 0.0% of book. The sizing grid independently returns Watchlist.

VEHICLE: None initiated. If it converts, see §6 — a defined-risk put spread at a later expiry, never equity
         (borrow) and never front-week long premium (IV at 2.1x realised, 41% spreads).

CONSENSUS POSITIONING: AGAINST a strong and STRENGTHENING consensus. 9 analysts, 9 Buy, 0 Hold, 0 Sell,
         average target $81.78 (+35%), and four targets RAISED in the last five weeks (TD Cowen $55 -> $85 on
         15 Jul) while five of nine cut FY2027 EPS over the same window. Numbers down, targets up. Named here
         rather than folded into the volatility tier.

INVALIDATION TRIGGERS (checkable, dated):
- 3 Aug 2026: Q2 exome/genome revenue / volume implies ASP >= $3,450 (vs the ~$3,333 guided). The price
  deterioration is arresting -> negative research view is weakening.
- 3 Aug 2026: FY2026 guidance RAISED above $490m, or exome/genome revenue growth guided above 25%.
  -> negative research view is wrong.
- Q2 10-Q: DSO falls below 55 days (from 67.7). The receivables build was a timing artifact, not a
  collections problem -> the earliest hard signal in the file is invalidated.
- Any quarter through FY2026: adjusted net income positive for the full year as guided -> the operating-
  leverage variant is wrong.
- Any close above $92.20 (200-day MA) -> the tape has rejected the thesis; move to Avoid on the short side.
- Conversely (short-side confirmation): a SECOND consecutive guidance cut on 3 Aug, or ASP printing below
  $3,250, would confirm the mechanism -- but see §5, that alone does not fix Gate 4 or 5.

4. Position sizing logic — the weighted composite, scored honestly

Component Weight Score Reasoning
Fundamental trajectory (Gate 1) 25% 0.75 Mechanism evidenced and company-disclosed; docked for the scorecard disagreement requiring an explanation
Variant vs. consensus (Gate 2) 25% 0.40 Marginal. −2.4% FY2026 revenue; 74% of the target gap is multiple; the Street has already cut hard
Catalyst and timing (Gate 3) 20% 0.85 Dated, 7 days out, discloses the exact metric in dispute
Valuation / payoff (Gate 4) 15% 0.10 Fails; the base-case target is above spot
Balance sheet and risk 10% 0.30 $71.7m net cash and a fresh $100m Blackstone facility — a headwind for a short: no financing forcing event
Technical / implementation (Gate 5) 5% 0.05 30.8% of float short, 41% option spreads, $106.6m of insider buying underneath
Composite 0.505 LOW

Volatility tier: HIGH — realised vol 95.9% annualised (>45% threshold); beta 1.98 (>1.5 threshold).

Sizing grid (house max single-name weight 5%): LOW conviction × HIGH volatility → "Below minimum size — round down to Watchlist." The grid returns the same answer the gates do, arrived at independently.

The framework's cap is also binding on its own: with Gate 4 failing outright, conviction is capped at Low regardless of how clean the rest of the analysis is — and a Low-conviction name is not a position.

5. Why passing is superior to taking the position

The question the framework says matters most.

A short here monetises a research view that is probably right about the business and wrong about the stock. The mechanism is real and the catalyst is a week away — but the market has already discounted it. The stock fell 49.2% in a single session on 5 May and is 64% below its 52-week high; the base case target sits above spot. What remains to be harvested is the difference between "ASP stabilises" and "ASP keeps falling," which is worth about 35% in the bear case — against a bull case that costs 70% and has ~$106.6m of discretionary insider capital, 30.79% of the float in weak short hands, and nine Buy ratings with rising targets standing behind it. That is a poor asymmetry, and it is why every plausible weighting of my own scenarios returns a negative number.

A long here would be buying the third-worst thing available: a bottom-decile-momentum name, 34% below its 200-day, whose realised price is falling, whose receivables are ageing, whose acquisition was written off, and whose guidance was cut 12% — into a print in seven days, at a valuation that already discounts the bull case. The +10.2% E[R] is real but its range straddles the cash hurdle, and it exists only because the bull case carries a 25% weight I cannot independently defend.

Not owning it costs 4.7% (cash) and nothing else. Passing preserves the option to act on 3 August with the disputed number in hand instead of guessing at it seven days early. That is the trade: wait one week for the free information.

6. Vehicle comparison (for the conversion case only — nothing is initiated)

Vehicle Assessment
Short equity Rejected. 30.79% of an 18.94m float, 5.22 days to cover, unknown-but-certainly-expensive borrow, unbounded loss, and a demonstrated ability to move +75% in eleven weeks.
Long-dated outright put Rejected. Naked long premium requires an explicit showing that the house expected move materially exceeds the option-implied move. It does not: 19.9% implied into a print, at 2.1× realised vol.
Front-week put (2026-08-07) Rejected. WGS260807P00060000 bid $4.38 / ask $6.81 — a 41% spread, IV 148.5%. Paying 41% of mid to express a one-week view is a fee, not a trade. IV crush after the 3-Aug print would remove a large fraction of premium even on a correct directional call.
Defined-risk put spread, Sep-2026 (the default, if it ever converts) The framework's default vehicle and the only structurally sane expression. Illustrative, at 2026-07-27 marks: buy WGS260918P00050000 (ask $4.58, IV 93.5%, δ −0.232) / sell WGS260918P00040000 (bid $0.98, IV 108.4%, δ −0.109) → net debit ~$3.60, max value $10.00, max profit $6.40, risk/reward 1.78:1, breakeven $46.40. Requires a −23% move by 18 Sep. Sells back the inflated wing premium rather than buying it. Not recommended today — Gates 4 and 5 fail, and the spread is only worth paying for after Q2 has confirmed the mechanism at a materially higher price than $60.54.
Long-side entry mechanism (documented so a conversion is executable, NOT to be used before the trigger) WGS260918P00045000 cash-secured put — bid $1.88, IV 98.4%, δ −0.159 → effective basis $43.12 if assigned, against a bear-case target of $39.15. Documented only. Selling a put IS long exposure and must not be used before the §7 trigger fires.

7. Book write-back

{
  "ticker": "WGS",
  "company": "GeneDx Holdings Corp.",
  "bias": "short-biased research view; NOT actionable — no position either direction",
  "status": "watchlist",
  "as_of": "2026-07-27",
  "memo_version": "1.4.2 (Tasks 1/2/3/5 only; pre-registered unmodified-framework baseline)",
  "price_at_review": 60.54,
  "probability_weighted_target": 66.71,
  "scenarios": {"bear": {"p": 0.30, "target": 39.15}, "base": {"p": 0.45, "target": 65.06}, "bull": {"p": 0.25, "target": 102.79}},
  "net_expected_return_at_spot": {"short_net": -0.217, "short_gross": -0.102, "long_gross": 0.102},
  "expected_return_range": {"short_net": [-0.322, -0.069], "long_gross": [-0.046, 0.207]},
  "cash_hurdle": 0.047,
  "gates_short": {"1": "PASS", "2": "PASS (marginal, 2A)", "3": "PASS", "4": "FAIL", "5": "FAIL", "6": "PASS (conflict named)"},
  "gates_long": {"1": "FAIL", "2": "FAIL", "3": "PASS", "4": "PASS (hurdle inside range)", "5": "PASS", "6": "FAIL"},
  "binding_gate": "4_expected_return (short side) — fails by 22-32pp across all plausible weights; 5_feasibility also fails",
  "conviction_composite": 0.505,
  "conviction": "LOW",
  "volatility_tier": "HIGH",
  "realised_vol": 0.959,
  "beta": 1.98,
  "size_now_pct_of_book": 0.0,
  "cluster": "life-science tools & diagnostics — 5th name in this cluster alongside GH, NTRA, TXG, TWST",
  "max_correlation_vs_book": {"NTRA": 0.34, "GH": 0.27, "TXG": 0.23, "TWST": 0.23, "SPY": 0.19},
  "correlation_note": "All pairs below the 0.60 threshold. Most idiosyncratic name in coverage — a reason to prioritise on conversion, never a reason to own now.",
  "converts_to_short_if": "ALL THREE: (a) Q2-2026 (3 Aug) prints exome/genome ASP below $3,250 OR a second guidance cut — fixing the Gate 2 magnitude; AND (b) short interest falls below ~20% of float on a subsequent FINRA settlement — fixing the Gate 5 crowding; AND (c) the stock is at or above ~$80 so the bear-case gap restores a positive net E[R] — fixing Gate 4. Vehicle on conversion: Sep/Dec defined-risk put spread, never equity, never front-week premium.",
  "converts_to_long_if": "~$40 (the bear-case target) AND at least one of: (i) DSO falls below 55 days, or (ii) two consecutive quarters of ASP at or above $3,450. Gate 1 for a long cannot be satisfied by price alone — an improving-fundamentals data point is mandatory.",
  "invalidation_of_short_bias": "Any close above $92.20 (200-day MA) -> Avoid, stop tracking the short side.",
  "next_checkpoint": "2026-08-03 — Q2-2026 results, after the close. Compute ASP = exome/genome revenue / volume and compare against the guided ~$3,333 and the H2-required $3,506.",
  "key_evidence": "Reset FY2026 guidance still embeds an H2 ASP of $3,506 vs H1 $3,315 (+5.7%) with no stated mechanism, while the 10-Q discloses a 5% decline in average reimbursement rates and DSO has gone 36 -> 68 days over five quarters. Offsetting: ~$106.6m of clustered discretionary insider buying (Casdin Capital, Keith Meister/Corvex) entirely after the guidance cut, and 30.79% of an 18.94m float already short."
}

8. Calibration note (standing obligation, CALIBRATION_WATCH.md)

Asking the required question — did each gate that rejected this name reject it for the right reason?